RGEN Stock Analysis: Buy, Sell, or Hold?
RGEN - Repligen Corp
$126.37
-0.20 (-0.16%)
▼
5d:
-3.44%
30d:
+11.47%
90d:
+8.61%
BUY
MODERATE Confidence
Analysis Updated: Jun 23, 2026 12:00 AM ET
Earnings: Aug 04, 2026
Get Alerted When RGEN Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
💡 BUY OPPORTUNITY: RGEN shows positive signals but monitor for confirmation. Market pricing in 5.7% decline. Moderate conviction.
💡 BUY OPPORTUNITY: RGEN shows positive signals but monitor for confirmation. Market pricing in 5.7% decline. Moderate conviction.
Long-Term Wealth Forecast (2031)
Based on Analyst Consensus Growth & Historical Valuation
0% (Stagnation)
50% (Hyper Growth)
EST. PRICE IN 2031
$123.93
Based on 14.5% avg growth
INTRINSIC VALUE TODAY
$76.95
Trading above historical range
How this is calculated: We use a Growth Decay Model: starting with analyst consensus growth (adjusted above) and gradually slowing it down to a long-term terminal rate (4%) by Year 5. This provides a more realistic valuation than assuming constant hyper-growth. We then apply a 25.0x Exit PE.
In-depth Analysis How we analyze
Valuation Analysis: RGEN is currently trading at $126.37, which is considered fair relative to its 30-day fair value range of $113.32 to $131.06. From a valuation perspective, the stock is trading at a discount (Forward PE: 49.6) compared to its historical average (59.2). Remarkably, the market is currently pricing in an annual earnings decline of 5.7% over the next few years. This pessimistic expectation contrasts with the company's recent 47.9% earnings growth, suggesting potential undervaluation if the company simply maintains stability.
Technical Outlook: Technically, RGEN is in a strong downtrend. Immediate support is located at $112.00, while resistance sits at $132.25.
Market Sentiment: The stock shows a mixed technical setup (40/100), with neutral trendline and momentum signals. Wall Street analysts see significant upside, with an average price target of $176.11 (+39.4%). Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Technical Outlook: Technically, RGEN is in a strong downtrend. Immediate support is located at $112.00, while resistance sits at $132.25.
Market Sentiment: The stock shows a mixed technical setup (40/100), with neutral trendline and momentum signals. Wall Street analysts see significant upside, with an average price target of $176.11 (+39.4%). Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Quick Decision Summary
Current Position
FAIR
Historical Trading Range
$113.32 -
$131.06
Company Quality Score
50/100
(HOLD)
Volume Confirmation
HIGH
Confidence Score
72.4%
All Signals
- NEUTRAL: Price in fair range
- NEUTRAL: Mixed technical signals (40/100)
- BULLISH: High volume confirmation
- BULLISH: Trading 39.4% below Wall St target ($176.11)
Trading Range Analysis
30-Day Trading Range
$113.32 -
$131.06
Current vs Trading Range
FAIR
Support & Resistance Levels
Support Level
$112.00
Resistance Level
$132.25
Current Trend
Strong Downtrend
Technical data as of
Jun 9, 2026
Fundamental Context
Forward P/E (Next Year Est.)
49.64
Wall Street Target
$176.11
(+39.4%)
Revenue Growth (YoY)
14.8%
Earnings Growth (YoY)
47.9%
Profit Margin
6.7%
Valuation Discount vs History
-5.7% cheaper
PE vs Historical
49.6 vs 59.2
CHEAP
Market-Implied Price Targets
If current PE multiple persists
Implied Growth (YoY):
-5.7%
(market-implied from PE analysis)
1-Year Target
$119.17
(-6%)
2-Year Target
$112.37
(-11%)
3-Year Target
$105.97
(-16%)
3-Yr Target (if PE normalizes)
(PE: 50→59)
$126.38
(0%)
3-Year Scenarios
Using analyst projected EPS growth
Bull:
(PE: 49.6, Growth: 27.2%)
$259.98
(+106%)
Base:
(SPY PE: 21.8, Growth: 27.2%)
$114.07
(-10%)
Bear:
(PE: 18.5, Growth: 27.2%)
$96.96
(-23%)
📈
Valuation based on Current Earnings
RECOVERY PLAY: Stock looks expensive now (64x PE), but valuation improves significantly next year (50x PE) as earnings recover.
Forward PE: 64.10 | Forward EPS (Implied): $1.97
Bull Case
$152.59
(+21%)
Analyst growth 15.0%, PE expands to 67.3
Base Case
$126.37
(0%)
Market implied 0.0%, PE stable at 64.1
Bear Case
$96.67
(-24%)
Severe decline -15.0%, PE contracts to 57.7
These are projections based on PE multiples and EPS growth scenarios, not predictions. Actual results may vary significantly.
💡
Upside Surprise Potential
If earnings stabilize (0% growth), PE could expand from 49.6 to 59.2
Stabilization Target:
$150.71
(+19.3%)
PE Expansion Potential:
+19.3%
Share & Embed Analysis
Last updated: June 23, 2026 7:57 PM ET
Data refreshes hourly during market hours. Next update: 8:57 PM
Data refreshes hourly during market hours. Next update: 8:57 PM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is RGEN showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Medical Instruments & Supplies Stocks
Top-rated stocks in Medical Instruments & Supplies by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
ISRG
Intuitive Surgical Inc |
BUY
33 analysts |
$565 | 57 HOLD |
|
ALC
Alcon AG |
STRONG BUY
27 analysts |
$88 | 54 HOLD |
|
RMD
ResMed Inc |
BUY
19 analysts |
$262 | 62 BUY |
|
COO
The Cooper Companies, Inc |
BUY
19 analysts |
$81 | 65 BUY |
|
WST
West Pharmaceutical Serv… |
STRONG BUY
13 analysts |
$359 | 59 HOLD |
